文献速递胸部肿瘤

EPAC-lung:晚期非小细胞肺癌循环肿瘤细胞的汇总分析

EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer.
PubMed 文献 · Eur J Cancer · 2019-06-27

该研究汇总9个欧洲中心中7个提供的550例晚期非小细胞肺癌患者个体数据,评估CellSearch检测的循环肿瘤细胞(CTC)计数与生存的关联。CTC≥2和≥5个/7.5 mL均与无进展生存期和总生存期缩短相关,将基线CTC计数加入临床病理模型可显著改善生存预测,但存在中心间异质性证据。

要点

  • CTC≥2个/7.5 mL与无进展生存期(HR=1.72)和总生存期(HR=2.18)缩短相关。
  • CTC≥5个/7.5 mL与无进展生存期(HR=2.21)和总生存期(HR=2.75)缩短相关。
  • 将基线CTC计数加入临床病理模型可显著改善生存预测,但存在中心间异质性证据。

核心结论

  • 这些数据证实CTC是晚期非小细胞肺癌无进展生存期和总生存期的独立预后指标,并揭示了一些中心间异质性的证据。
  • 将CTC计数加入完整的临床病理预测模型可改善预后判断。

研究设计与样本

  • 研究为汇总分析,纳入9个欧洲非小细胞肺癌CTC中心中7个中心提供的550例晚期非小细胞肺癌患者个体数据。
  • 患者来自2003年1月至2017年3月期间参与CellSearch CTC研究的晚期非小细胞肺癌患者。
  • 采用按中心分层的Cox回归模型分析CTC计数与生存的关联,并使用似然比统计量和c指数评估CTC对临床病理预后模型的附加价值。

主要发现

  • CTC≥2个/7.5 mL与无进展生存期缩短相关(HR=1.72,p<0.001),与总生存期缩短相关(HR=2.18,p<0.001)。
  • CTC≥5个/7.5 mL与无进展生存期缩短相关(HR=2.21,p<0.001),与总生存期缩短相关(HR=2.75,p<0.001)。
  • 将基线CTC计数加入似然比临床病理模型可显著改善生存预测(对数转换CTC p<0.001;≥2 CTCs p<0.001;≥5 CTCs p≤0.001,两个生存终点均如此)。
  • 使用c指数模型时观察到中等程度的改善。
  • 存在一些中心间异质性的证据,尤其在检查连续CTC计数时。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 存在一些中心间异质性的证据,尤其在检查连续CTC计数时。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: We assessed the clinical validity of circulating tumour cell (CTC) quantification for prognostication of patients with advanced non-small cell lung cancer (NSCLC) by undertaking a pooled analysis of individual patient data. METHODS: Nine European NSCLC CTC centres were asked to provide reported/unreported pseudo-anonymised data for patients with advanced NSCLC who participated in CellSearch CTC studies from January 2003 to March 2017. We used Cox regression models, stratified by centres, to establish the association between CTC count and survival. We assessed the added value of CTCs to prognostic clinicopathological models using likelihood ratio (LR) statistics and c-indices. RESULTS: Seven out of nine eligible centres provided data for 550 patients with prognostic information for overall survival. CTC counts of ≥2 and ≥ 5 per 7·5 mL were associated with reduced progression-free survival (≥2 CTCs: hazard ratio [HR] = 1.72, p < 0·001; ≥5 CTCs: HR = 2.21, p < 0·001) and overall survival (≥2 CTCs: HR = 2·18, p < 0·001; ≥5 CTCs: HR = 2·75, p < 0·001), respectively. Survival prediction was significantly improved by addition of baseline CTC count to LR clinicopathological models (log-transformed CTCs p < 0·001; ≥2 CTCs p < 0·001; ≥5 CTCs p ≤ 0·001 for both survival end-points), whereas moderate improvements were observed with the use of c-index models. There was some evidence of between-centre heterogeneity, especially when examining continuous counts of CTCs. CONCLUSIONS: These data confirm CTCs as an independent prognostic indicator of progression-free survival and overall survival in advanced NSCLC and also reveal some evidence of between-centre heterogeneity. CTC count improves prognostication when added to full clinicopathological predictive models.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Lindsay CR, Blackhall FH, Carmel A, et al. EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer. Eur J Cancer. 2019. PMID: 31254940. doi:10.1016/j.ejca.2019.04.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。